Home  /  Resource Library  /  ORELABRUTINIB-LENALIDOMIDE-RITUXIMAB (OLR) IN PATIENTS WITH UNTREATED MANTLE CELL LYMPHOMA (MCL): A PROSPECTIVE, MULTICENTER, SINGLE-ARM PHASE 2 POLARIS STUDY IN CHINA

ORELABRUTINIB-LENALIDOMIDE-RITUXIMAB (OLR) IN PATIENTS WITH UNTREATED MANTLE CELL LYMPHOMA (MCL): A PROSPECTIVE, MULTICENTER, SINGLE-ARM PHASE 2 POLARIS STUDY IN CHINA

ICML 2023